Acute Myeloid Leukemia in Remission Clinical Trials

7 recruiting

Acute Myeloid Leukemia in Remission Trials at a Glance

7 actively recruiting trials for acute myeloid leukemia in remission are listed on ClinicalTrialsFinder across 6 cities in 3 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Boston, Seattle, and Antwerp. Lead sponsors running acute myeloid leukemia in remission studies include Massachusetts General Hospital, Medical College of Wisconsin, and Fred Hutchinson Cancer Center.

Browse acute myeloid leukemia in remission trials by phase

Treatments under study

About Acute Myeloid Leukemia in Remission Clinical Trials

Looking for clinical trials for Acute Myeloid Leukemia in Remission? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Acute Myeloid Leukemia in Remission trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Acute Myeloid Leukemia in Remission clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 1

Ziftomenib Maintenance Post Allo-HCT

Acute Myeloid LeukemiaAcute Myeloid Leukemia in RemissionKMT2A Rearrangement+1 more
Massachusetts General Hospital22 enrolled2 locationsNCT06440135
Recruiting
Phase 2

Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT

Acute Myeloid Leukemia in Remission
Nantes University Hospital302 enrolled23 locationsNCT05917405
Recruiting
Phase 2

Pilot Study of Reduced Venetoclax Exposure

Acute Myeloid Leukemia in Remission
Northwell Health41 enrolled1 locationNCT07163793
Recruiting
Phase 1Phase 2

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Hematopoietic and Lymphoid Cell NeoplasmAcute Myeloid Leukemia in RemissionChronic Myelomonocytic Leukemia+9 more
Fred Hutchinson Cancer Center30 enrolled1 locationNCT03670966
Recruiting
Not Applicable

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing

LeukemiaAcute Myeloid Leukemia in RemissionLymphoblastic Lymphoma+10 more
Medical College of Wisconsin40 enrolled1 locationNCT05794880
Recruiting
Phase 1

Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)

Hematologic MalignancyGvHDGVHD,Acute+8 more
Tr1X, Inc.36 enrolled5 locationsNCT06462365
Recruiting
Phase 2

Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning

Multiple MyelomaAcute Myeloid Leukemia in RemissionMyelodysplastic Syndromes+5 more
University of Liege114 enrolled10 locationsNCT03852407